Probing the presence of the ligand‐binding haem in cellular nitric oxide receptors
Open Access
- 1 April 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (7) , 1495-1504
- https://doi.org/10.1038/sj.bjp.0707687
Abstract
Background and purpose: Nitric oxide (NO) acts on receptors coupled to guanylyl cyclase (GC), leading to cGMP accumulation. The NO binding site is a haem group, oxidation or loss of which diminishes NO‐stimulated activity. Agonists reportedly engaging both these NO‐insensitive forms have emerged. Here we characterize the effect of a prototype compound (BAY 58‐2667) and use it to assess the haem status of cellular GC. Experimental approach: GC activity measurements were made on the purified protein and on rat platelets. Key results: Experiments on purified GC showed that the target for BAY 58‐2667 is the haem‐free GC, not the haem‐oxidized form. The efficacy of BAY 58‐2667 was about half that shown normally by NO. In platelets, BAY 58‐2667 was a potent GC activator (EC50 ∼15 nM) but the maximum effect was only about 1% of that achievable with NO. Nevertheless, it was enough to evoke cGMP‐dependent protein phosphorylation. Profound (85 %) desensitization of NO‐evoked GC activity did not alter the effectiveness of BAY 58‐2667. Haem oxidation, however, increased the efficacy of BAY 58‐2667 by 22‐fold, implying that about half the cellular GC was then haem‐free. Oxidation appeared to enhance the rate of haem dissociation from purified GC. Conclusions and implications: Compounds such as BAY 58‐2667 are useful for probing the occupancy of the haem pocket of NO receptors in cells but not for distinguishing oxidized from reduced haem. In vivo, such compounds are likely to be particularly effective in conditions where there is deficient haem incorporation or enhanced haem loss. British Journal of Pharmacology (2008) 153, 1495–1504; doi:10.1038/sj.bjp.0707687; published online 21 January 2008Keywords
This publication has 40 references indexed in Scilit:
- Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart FailureHypertension, 2007
- Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vesselsJournal of Clinical Investigation, 2006
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Nitric oxide activation of guanylyl cyclase in cells revisitedProceedings of the National Academy of Sciences, 2006
- Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular systemJournal of Clinical Investigation, 2006
- Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular RemodelingCirculation, 2006
- Kinetics of a Cellular Nitric Oxide/cGMP/Phosphodiesterase-5 PathwayJournal of Biological Chemistry, 2004
- Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate CyclaseJournal of Biological Chemistry, 2004
- Increased Nitrovasodilator Sensitivity in Endothelial Nitric Oxide Synthase Knockout MiceHypertension, 2000
- A Functional Heme‐Binding Site of Soluble Guanylyl Cyclase Requires Intact N‐Termini of α1 and β1 SubunitsEuropean Journal of Biochemistry, 1996